Latest news with #KezarLifeSciences
Yahoo
28-05-2025
- Business
- Yahoo
Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 28, 2025--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that Chris Kirk, Chief Executive Officer and Co-founder, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 2:35 pm ET in New York, NY. A webcast of the panel discussion will be available on the "Events & Presentations" section of the Company's website at Following the event, an archived webcast will be available on the Kezar website for 90 days. About Kezar Life Sciences Kezar Life Sciences is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases. Zetomipzomib, a selective immunoproteasome inhibitor, is currently being evaluated for autoimmune hepatitis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. For more information, visit and follow us on LinkedIn, Facebook, Twitter and Instagram. View source version on Contacts Investor and Media Contact:Gitanjali JainSenior Vice President, Investor Relations and External AffairsKezar Life Sciences, Sign in to access your portfolio
Business Wire
28-05-2025
- Business
- Business Wire
Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that Chris Kirk, Chief Executive Officer and Co-founder, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 2:35 pm ET in New York, NY. A webcast of the panel discussion will be available on the 'Events & Presentations' section of the Company's website at Following the event, an archived webcast will be available on the Kezar website for 90 days. About Kezar Life Sciences Kezar Life Sciences is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases. Zetomipzomib, a selective immunoproteasome inhibitor, is currently being evaluated for autoimmune hepatitis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. For more information, visit and follow us on LinkedIn, Facebook, Twitter and Instagram.
Business Insider
14-05-2025
- Business
- Business Insider
TD Cowen Reaffirms Their Buy Rating on Kezar Life Sciences (KZR)
In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Kezar Life Sciences (KZR – Research Report). The company's shares closed today at $4.20. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. According to TipRanks, Nadeau is a 2-star analyst with an average return of 0.4% and a 37.63% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Neurocrine, and Voyager Therapeutics. Kezar Life Sciences has an analyst consensus of Strong Buy, with a price target consensus of $12.50. The company has a one-year high of $9.18 and a one-year low of $3.62. Currently, Kezar Life Sciences has an average volume of 31.91K.
